Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityLiabilities and Shareholders EquityOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Greenwich LifeSciences (GLSI) Accumulated Expenses (2019 - 2025)

Greenwich LifeSciences filings provide 7 years of Accumulated Expenses readings, the most recent being $306281.0 for Q3 2025.

  • Quarterly Accumulated Expenses rose 352.91% to $306281.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $306281.0 through Sep 2025, up 352.91% year-over-year, with the annual reading at $306281.0 for FY2024, 704.12% up from the prior year.
  • Accumulated Expenses hit $306281.0 in Q3 2025 for Greenwich LifeSciences, up from $82852.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $306281.0 in Q4 2024 and bottomed at $1083.0 in Q2 2023.
  • Average Accumulated Expenses over 5 years is $80457.2, with a median of $43029.0 recorded in 2024.
  • The largest annual shift saw Accumulated Expenses plummeted 89.31% in 2022 before it soared 1543.31% in 2024.
  • Greenwich LifeSciences' Accumulated Expenses stood at $164327.0 in 2021, then plummeted by 74.4% to $42060.0 in 2022, then dropped by 9.44% to $38089.0 in 2023, then surged by 704.12% to $306281.0 in 2024, then changed by 0.0% to $306281.0 in 2025.
  • Per Business Quant, the three most recent readings for GLSI's Accumulated Expenses are $306281.0 (Q3 2025), $82852.0 (Q2 2025), and $84362.0 (Q1 2025).